Peptides such as oral BPC-157, oral larazotide , oral KPV, and injectable thymosin beta-4 (T4) are well tolerated and can be seamlessly integrated into existing protocols, even for the most sensitive patients
It is not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, food use, cosmetic use, or household use
Always consult with a healthcare provider before starting any new peptide therapy, as these compounds can have powerful effects and may interact with other medications or treatments
Keeping up with codes, modifiers, and payer rules with additional paperwork is not an easy task
Store at 20 C (4 F) or below
In vitro assays show that retatrutide demonstrates enhanced potency at the human GIPR compared to natural GIP